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ABSTRACT
Previous studies indicate that overexpression of
N-methylpurine DNA glycosylase (MPG) dramatically
sensitizes cells to alkylating agent-induced cytotox-
icity. We recently demonstrated that this sensitivity
is preceded by an increased production of AP sites
and strand breaks, confirming that overexpression
of MPG disrupts normal base excision repair and
causes cell death through overproduction of toxic
repair intermediates. Here we establish through site-
directed mutagenesis that MPG-induced sensitivity to
alkylation is dependent on enzyme glycosylase activ-
ity. However, in contrast to the sensitivity seen to het-
erogeneous alkylating agents, MPG overexpression
generates no cellular sensitivity to MeOSO2(CH2)2-
lexitropsin, an alkylator which exclusively induces
3-meA lesions. Indeed, MPG overexpression has
been shown to increase the toxicity of alkylating
agents that produce 7-meG adducts, and here we
demonstrate thatMPG-overexpressing cellshavedra-
matically increased removal of 7-meG from their DNA.
These data suggest that the mechanism of MPG-
induced cytotoxicity involves the conversion of
non-toxic 7-meG lesions into highly toxic repair inter-
mediates. This study establishes a mechanism by
which a benign DNA modification can be made
toxic through the overexpression of an otherwise
well-tolerated gene product, and the application of
this principle could lead to improved chemothera-
peutic strategies that reduce the peripheral toxicity
of alkylating agents.
INTRODUCTION
Many cancer chemotherapeutics achieve their medicinal
effects by producing DNA lesions that trigger the interruption
of cell division and ultimately lead to cell death. However,
because chemotherapy does not exclusively target tumor cells,
the adverse effects on normal tissues limit the doses that can be
administered to patients (1). Because peripheral side effects
limit treatment, tumor cells are often inadequately eliminated
and the outgrowth of drug resistant clones is allowed. In order
to advance cancer treatment toward a cure, chemotherapy
needs to be made both more specific and more effective.
Chemotherapeutic drugs frequently modify DNA through
oxidation and alkylation reactions (2), producing DNA adducts
that are identified and replaced by the base excision repair
(BER) pathway (3). BER involves the recognition and removal
of damaged bases by a DNA glycosylase, followed by incision
of the resulting abasic (AP) site by AP endonuclease (Ape 1),
DNA synthesis by polymerase and strand ligation by DNA
ligase (4). This pathway, therefore, involves the processing of
modest structural DNA damage through toxic baseless and
strand-interrupted species (5–7), which may transiently replace
less toxic or non-toxic DNA lesions in the course of restoring
the DNA sequence.
We have been interested in intervening into the BER path-
way to improve the efficacy of cancer chemotherapy. Recent
studies show that transient overexpression of N-methylpurine
DNA glycosylase (MPG) increases the cytotoxicity of alky-
lating agents such as temozolomide in breast cancer cells (8).
Cells that overexpress MPG also have higher numbers
of alkylating agent-induced AP sites and/or single-stranded
DNA breaks as well as double-stranded DNA breaks, which
are the likely cause of this increased toxicity. These data
suggest that overexpression of MPG creates an ‘imbalance’
in the BER pathway which leads to saturation of downstream
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repair enzymes and accumulation of toxic intermediates (8,9).
Implicit is the idea that the intermediates produced are more
detrimental to the cell that the alkylated base lesions from
which they originate. Having established the accumulation
of toxic BER intermediates, we turned our attention toward
identifying the products of alkylation that lead to MPG
overexpression-induced sensitivity.
The major site of alkylation for all methylating agents is the
highly nucleophilic N7 nitrogen of guanine. N7-methylguanine
(7-meG) makes up 70–90% of the adducts produced by
methylation, with far fewer modifications occurring at the
N3 position of adenine (3-meA) and fewest at the O6 position
of guanine (O6-meG). Though quantitatively the most signi-
ficant of these principal lesions, 7-meG has little, if any, effect
on the cell. DNA duplex structure is unaltered by the addition
of this methyl group, and 7-meG has the same coding prop-
erties as unmodified guanine. In fact, 7-meG is neither muta-
genic nor toxic and appears to be in all ways harmless, as it is
tolerated by the cell for generations. In contrast, the minor
lesions 3-meA and O6-meG are primarily responsible for the
cellular effects of methylation: 3-meA inhibits DNA poly-
merase and arrests DNA synthesis, leading to sister chromatid
exchange, chromosome breaks and cell death; O6-meG is
highly mutagenic and may, under certain circumstances,
block DNA replication.
MPG recognizes and removes 3-meA and 7-meG (10), the
most common methylated DNA lesions (11). Increased
alkylation-induced cytotoxicity in MPG-overexpressing cells
probably reflects an increased load of intermediates produced
by incomplete repair of 3-meA adducts, 7-meG adducts or
both. We decided to investigate the mechanism of MPG-
induced alkylation sensitivity, with particular attention on
the inciting lesions.
Here we demonstrate, through the use of inactive site-
directed mutants, that MPG-driven alkylation sensitivity is
dependent on the enzyme’s glycosylase activity. We addition-
ally found that, although MPG overexpression causes sensit-
ivity to classic monofunctional alkylating agents, it imparts
no sensitivity to the 3-meA specific agent MeOSO2(CH2)2-
lexitropsin (Me-lex), arguing against a role for 3-meA removal
in generating alkylating agent sensitivity. Specific adduct
analysis revealed that MPG overexpression causes rapid,
near-total removal of 7-meG from the DNA. This strongly
implicates the conversion of non-toxic 7-meG adducts to
toxic repair intermediates in explaining MPG-induced alkyla-
tion sensitivity. The exchange of harmless base changes for
toxic genetic interruptions represents a novel approach to
cancer treatment that could decrease side effects and increase
the likelihood of a cure.
MATERIALS AND METHODS
Cell lines and culture conditions
The human mammary gland adenocarcinoma cell line
MDA-MB231 was purchased at passage number 29 from
the American Type Culture Collection (ATCC, Manassas,
VA, USA). Cells were grown at 37C in a 5% CO2 water-
humidified chamber (Forma Scientific, Marietta, OH, USA),
and cultured in RPMI 1640 media (Invitrogen Corporation,
Carlsbad, CA, USA) supplemented with 10% fetal bovine
serum (Hyclone Laboratories, Logan, UT, USA). A 1%
penicillin/streptomycin antimicrobial solution (Invitrogen)
was included in stable stock culture but not in experimental
cultures, and cells were replaced by fresh frozen stocks before
25 passages in our lab.
Site-directed mutagenesis
Two inactive site-directed mutants of HA-MPG were con-
structed using a QuikChange Site-Directed Mutagenesis kit
(Stratagene, La Jolla, CA, USA), according to the manu-
facturer’s protocol. An alanine was substituted for glutamic
acid residue 125 (E125A), using a mutagenic primer (50-
CGCATCGTGGAGACCGCGGCATACCTGGGGCC-30)
and its complement, both containing a point mutation (under-
lined) that would change the glutamic acid codon to an alanine
(bold). An additional MPG mutant was generated by substi-
tuting tyrosine 162 with alanine, using the following primer
and its complement: 50-CCTGTACGTGTACATCATTGC-
CGGCATGTACTTCTGC-30 (mutation underlined; codon
change in bold). These two mutants have minimal glycosylase
activity (12). Glu-125 deprotonates a bound water molecule
that is required for glycosylic bond cleavage. However, the
E125A mutation eliminates glysosylase activity. Tyr-162
intercalates into the minor groove, flipping a damaged nucle-
otide into the enzyme’s active site, where cleavage can
occur. Y162A mutants have minimal glycosylase activity.
Site-directed mutagenesis with these mutagenic primers was
performed on HA-MPG in the pCR2.1 vector, and the result-
ing constructs were sequenced to verify that the desired
mutations had been introduced into the HA-MPG sequence.
Both mutants were then moved into the modified adenoviral
shuttle vector pacAd5 IRES EGFP, using BamHI and XhoI
restriction sites.
Adenoviral infection
The HA-MPG-, HA-E125A- and HA-Y162A-containing
adenoviral shuttle vectors and empty vector control (pacAd5
IRES2EGFP) were sent to the University of Iowa Gene
Transfer Vector Core Laboratory for production and titering
of replication-defective recombinant adenovirus (13). Adeno-
virus stocks (Ad5 IRES2EGFP, Ad5 E125A, Ad5 Y162A and
Ad5 HA-MPG) were aliquoted and stored at 80C until the
time of infection. Adenoviral infection was performed as pre-
viously reported (8), using MDA-MB231 breast cancer cells at
60–90% confluence that were washed with phosphate-buffered
saline (PBS), trypsinized for 10–15 min and resuspended in a
known volume of medium. Identical cell numbers ranging
from 5 · 106 to 6 · 106 cells were pelleted and resuspended
in 50 ml of PBS and purified adenovirus at a multiplicity
of infection of 15 IU/cell. Infections were carried out for 3 h
at 37C in a 5% CO2 water-humidified chamber with gentle
agitation every 20–30 min. Infected cells were resuspended
in 10 ml 10% RPMI, mixed thoroughly and plated for cell
survival assays. Infection efficiencies of transduced cells were
determined 24 h after infection by measuring EGFP fluores-
cence intensities of 104 cells using a FACSCalibur fluores-
cence activated cell sorter (Becton-Dickinson, San Jose, CA,
USA). Results were analyzed with Cell-Quest 3.3 software
(Becton-Dickinson). EGFP expression levels were also visu-
alized by fluorescence microscopy using a Nikon TS-100F
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microscope fitted with a Nikon fluorescence system (Nikon,
Tokyo, Japan).
Western blot analysis
Western blots were performed according to the Invitrogen
NuPage protocol (Invitrogen) as outlined previously (8).
Briefly, 20 mg protein was analyzed on a 10% Bis-Tris
NuPAGE gel and transferred to a nitrocellulose (NC) mem-
brane. Membranes were probed using monoclonal MPG
antibody (kindly provided by Dr Rabindra Roy, University
of Texas Medical Branch, Galveston, TX, USA), followed
by horseradish peroxidase-conjugated rabbit anti-mouse
IgG (Chemicon International, Temecula, CA, USA). Antibody
binding was detected using chemiluminescence (Roche
Diagnostics Corp., Indianapolis, IN, USA), and equal loading
was confirmed by probing with pan Actin monoclonal Ab
(NeoMarkers Inc., Fremont, CA, USA).
DNA isolation
DNA was isolated from cultured cells using the PureGene
DNA extraction kit (Gentra Systems Inc., Minneapolis,
MN, USA). Briefly, cell pellets were thawed and lysed in
lysis buffer supplemented with 20 mM 2,2,6,6-tetramethyl-
piperidinoxyl (TEMPO; Aldrich). Protein was precipitated
and removed by centrifugation, and the DNA/RNA in the
supernatant was precipitated with isopropyl alcohol. The
DNA/RNA pellet was resuspended in lysis buffer with
20 mM TEMPO and incubated with RNase A (100 mg/ml)
at 37C for 30 min, followed by protein and DNA precipita-
tion. The DNA pellet was resuspended in sterilized distilled
water with 2 mM TEMPO, and DNA samples were stored at
80C until analysis.
Drug treatment
Infected cells were treated with DNA-damaging agents 24 h
after adenoviral exposure (8). Infected cells were treated
with Me-lex (a kind gift from Dr Barry Gold, University of
Nebraska, Omaha, NE, USA), temozolomide (a kind gift from
Dr Robert Bishop, Schering Corp., Kenilworth, NJ, USA),
methylmethane sulfonate (MMS), ethyl nitrosourea (ENU),
1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), mitomycin C
(MMC), Etoposide (all from Sigma Chemical Co., St Louis,
MO, USA), thiotepa (Immunex Corp., Seattle, WA, USA)
or cisplatin (Bristol Myers Squibb Co., Princeton, NJ, USA)
for 1 h at 37C in 5% CO2. Drug-containing media was
removed and replaced with fresh growth medium, and cells
were incubated for 24–48 h.
Cell survival assay
Survival of HA-MPG-overexpressing cells was measured 24
and 48 h after drug treatment using the tetrazolium-based MTS
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymeyhoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium] dye reduction assay
(8,14,15) (Promega, Madison, WI, USA). Infected cells were
incubated with MTS/PMS solution for 1–4 h at 37C in a 5%
CO2 humidified incubator, and absorbance at 490 nm was
measured in a tunable microplate reader (Molecular Devices,
Sunnyvale, CA, USA).
Measurement of N7-methylguanine adducts in cells
treated with MMS
Two independent techniques were used to measure 7-meG
adducts Infected cells expressing IRES EGFP vector control
or HA-MPG were treated with MMS for 1 h starting 24 h after
adenoviral infection. MMS-containing medium was removed
and replaced with fresh growth medium. Cells were harvested
0, 2, 5 and 25 h after drug treatment, washed three times with
PBS and collected by scraping. Cell pellets were frozen at
80C until DNA isolation and adduct analysis.
N7-meG HPLC-ECD
Quantification of 7-meG in extracted cellular DNA was per-
formed by high-performance liquid chromatography (HPLC)
with electrochemical detection (ECD) using a modification
of the method published by Park and Ames (16). Between
12 and 55 mg of extracted DNA was adjusted to a final volume
of 100 ml with ddH2O. The DNA samples were subjected to
neutral thermal hydrolysis at 100C for 30 min to quantitat-
ively release 7-meG. Depurinated DNA was precipitated by
the addition of 10 ml of cold 1 M HCl and removed by cent-
rifugation. To the supernatant, 100 ml of HPLC mobile phase
buffer and 9 ml of 1 M NaOH were added. Bases released into
the supernatant were separated by reversed phase chromato-
graphy (Beckman Ultrasphere C18 column, 25 cm · 4.6 mm,
5 mm particle size) using 50 mM potassium phosphate buffer,
pH 5.5/methanol [98:2 (v/v)] as mobile phase at a flow rate of
1 ml/min. The 7-meG adduct was detected by a CoulArray
electrochemical detector (ESA, Chelmsford, MA, USA) mon-
itoring oxidation at 500, 600, 700 and 800 mV. The concen-
tration of 7-meG was determined by comparing the peak areas
resulting from the ECD of cell samples with those of a series
of standards.
Immuno-slot-blot for N7-meG
Experimental samples (1 mg) or a reference standard
containing a known amount of N7-meG were denatured in
200 ml TE buffer plus 20 ml 2N NaOH at 37C for 15 min.
This treatment generates 2,6-diamino-4-hydroxy-5-N-methyl-
formamidopyrimidine (imidazole ring-opened 7-meG) from
7-meG. After addition of an equal volume of 2 M ammonium
acetate, samples were applied to NC filters using a Minifold II
(Schleicher & Schuell). The filters were soaked in 5· SSC
(0.75 M NaCl, 75 mM sodium citrate, pH 7.0) for 15 min, dried
and baked in a vacuum oven for 2 h at 80C. Filters were
incubated for 2 h at 37C with blocking buffer [20 mM Tris–
HCl (pH 7.5), 0.1 M NaCl, 1 mM EDTA, 0.5% casein and
0.1% deoxycholic acid], followed by a 2 h incubation at 37C
in blocking buffer containing antibody (1:10 000) to imidazole
ring-opened 7-methylguanosine (17). The filters were washed
extensively in washing buffer [20 mM Tris–HCl (pH 7.5),
0.26 M NaCl, 1 mM EDTA, 0.1% Tween-20] and treated
with a labeled polymer (peroxidase-labeled polymer conjug-
ated to goat anti-rabbit and goat anti-mouse immunoglobulins)
(Daco) diluted 1:1000 in hybrid buffer. After rinsing the
NC membrane, the enzymatic activity on the membrane
was visualized by enhanced chemiluminescence reagents
(Amersham). The NC filter was exposed to X-ray film, and
the developed film was analyzed using a Kodak image analysis
system.
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RESULTS
The role of MPG glycosylase activity in sensitivity to
DNA alkylation damage
In order to determine whether MPG-driven alkylator sensit-
ivity depends on the enzyme’s glycosylase activity, two MPG
mutants, Y162A and E125A, were constructed to be select-
ively inactive in their ability to bind substrate bases or excise
them, respectively. Tyrosine 162 plays a role in flipping
nucleotides into the enzyme active site, which is required
for lesion recognition and DNA binding; glutamic acid 125
then activates a water molecule that is required for hydrolysis
of the glycosyl bond (12).
MDA-MB231 breast cancer cells were infected with recom-
binant adenovirus carrying HA-tagged wild-type, Y162A or
E125A MPG or vector control (Figure 1). Western blot ana-
lysis at 24 h post-infection showed that these three MPG
variants were equivalently overexpressed (data not shown).
Cells were treated with the monofunctional alkylating agent
MMS or the clinical chemotherapeutic temozolomide 24 h
post-infection and incubation was continued for 24 h.
Cell survival was measured using the MTS assay. The results
showed that overexpression of wild-type but neither mutant
MPG increased the toxicity of MMS and temozolomide
relative to the vector control (Figure 1). This proves that
the sensitizing effect of MPG overexpression is a result of
the enzyme’s glycosylase activity, and further indicates that
both binding and excisional components of MPG glycosylase
activity are required for the increased alkylation toxicity
created by high levels of wild-type MPG.
Lesion specificity of MPG-dependent sensitivity
to DNA alkylation damage
Alkylating agents react with nucleophilic centers to form
several distinct covalent adducts with DNA bases. The most
common sites of alkylation include (in order of prevalence)
N7-guanine, N3-adenine and O6-guanine (11). Most simple
methylating agents generate predominantly 7-meG adducts
and a smaller number of 3-meA and O6-meG adducts.
MPG has a relatively broad substrate specificity and it
excises many DNA adducts including 7-meG (11), 3-meA
(10), 3-methylguanine (18,19), hypoxanthine (20), 1,N6-
ethenoadenine (21), 3,N2-ethenoguanine and 8-oxoguanine
(22). Because of their prevalence, 7-meG and 3-meA are
principal alkylation substrates of MPG. However, the lesions
responsible for increased alkylating agent-induced cytotox-
icity in MPG-overexpressing cells remain unknown.
In contrast, the mixture of DNA lesions resulting from
most alkylating agents, Me-lex, selectively generates 3-meA
adducts and was used here to investigate their role in MPG-
dependent cytotoxicity. Me-lex is a methyl sulfonate ester
tethered to a neutral N-methylpyrrolecarboxamide-based
dipeptide (lex), which confers sequence-selective minor
groove DNA binding (23,24). Of the adducts formed by
Me-lex, >99% are 3-meA, and a very small fraction are
7-meG (25) or O6-meG (26), making Me-lex extremely useful
for determining the role of 3-meA lesions in MPG-dependent
cytotoxicity. When wild-type cells or cells overexpressing
MPG were treated with Me-lex, the results clearly showed
that overexpression of MPG had no effect on cell survival
(Figure 2), demonstrating that 3-meA is not the lesion
involved in MPG-induced alkylator sensitivity.
Quantitative analysis of 7-meG adducts in MMS-treated
wild-type and MPG-overexpressing cells
DNA adducts at the highly nucleophilic N7 position of guanine
account for 70–90% of the base modifications generated
by monofunctional methylating agents such as MMS (11).
Despite its abundance, 7-meG is a relatively innocuous DNA
modification, because it does not alter DNA structure, is not
mutagenic and does not lead to cell death (27–30). Still, its
relative electron deficiency causes 7-meG to be recognized
and excised by MPG, even though it presents no threat to
the cell. No compounds are currently known to generate
7-meG exclusively in the DNA, but all commonly used
methylating agents generate a preponderance of this adduct.
A quantitative analytical approach was developed to establish
the possible role of 7-meG adducts in MPG-dependent
alkylation-induced cytotoxicity.
Wild-type and MPG-overexpressing cells were treated with
sensitizing doses of MMS and cells were then harvested 0, 2, 5
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Figure 1. Survival of drug-treated MDA-MB231 cells overexpressing wild-
type or mutant MPG. Vector control (IRES EGFP), wild-type MPG (HA-MPG),
E125A mutant MPG (E125A) or Y162A mutant MPG (Y162A) overexpressing
cells were treated with either MMS (A) or temozolomide (TMZ) (B) at the
indicated concentrations and survival was determined as described in Materials
and Methods. Data points are the average of >3 independent experiments.
Two-way ANOVA analysis was used to evaluate statistical significance.
The significance is indicated as *P < 0.05 or **P < 0.01.
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and 25 h post-treatment. 7-meG adducts in the DNA were
quantified by two independent methods: HPLC with ECD
and immuno-slot-blotting. The results shown in Figure 3
indicate that a large number of 7-meG adducts accumulate
in wild-type cells following MMS treatment. In contrast,
very few 7-meG adducts are observed at any time point
in cells overexpressing MPG. In fact, the level of 7-meG
in alkylating agent-treated MPG-overexpressing cells was
reduced to at or near baseline at every time point, and in
the more quantitative HPLC assay, levels were below the
limit of detection except immediately following the highest
drug exposure. These data suggest that MPG rapidly and effi-
ciently converts 7-meG adducts into the downstream repair
intermediates previously demonstrated (8). This striking, near-
total exchange of benign 7-meG bases for toxic baseless and
strand-broken DNA establishes a role for 7-meG removal in
the sensitizing effect of MPG overexpression.
MPG-dependent cytotoxicity in the presence of
N7-guanine reactive compounds
To determine whether methylation at the N7 position of
guanine is specifically responsible for MPG-induced alkyla-
tion sensitivity, a number of drugs that append other forms of
damage to guanine were analyzed for their impact on MPG-
overexpressing cell survival. These compounds were ENU,
BCNU, thiotepa (N,N0,N0,-triethylenethiophosphoramide),
4-hydroxycyclophosphamide (4-HC), MMC and cisplatin.
ENU is a monofunctional alkylating agent that generates
ethylation damage at the same N7G, O6G and N3A positions
as its methylating counterpart, MNU, which was previously
shown to sensitize MPG-overexpressing cells. BCNU is a
monofunctional alkylating agent that has some selectivity
for chloroethylating guanine at the O6 position (11,31).
Thiotepa is a clinical bifunctional alkylating agent that
generates N7-guanine- and N3-adenine-targeted aminoethyl
adducts (32), which can undergo depurination or imidazole
ring-opening to AP sites or 2,6-diamino-4-hydroxy-5-
formamidopyrimidine (FaPyGua) and 4,6-diamino-5-
formamidopyrimidine (FaPyAde) (33). 4-HC, the activated
form of the clinical chemotherapeutic cyclophosphamide
and its structural isomer ifosphamide, is a bifunctional
alkylating agent with bischloroethyl side chains that
generates N7-guanine-linked interstrand crosslinks in G–X–
C-containing sequences (34). Similarly, MMC, an aziridin
ring-containing DNA cross-linking agent (35), forms N7-
guanine-linked interstrand crosslinks. Cisplatin is a square
planar platinum-containing complex with two cis-oriented
chloride leaving groups that preferentially generates intras-
trand DNA crosslinks in dGpdG and dApdG motifs (34,36).
MPG recognizes and binds to cisplatin-DNA adducts, but not
does not excise them in vitro (37).
Wild-type and MPG-overexpressing cells were treated with
the DNA-damaging agents discussed above and survival curves
were determined 24 or 48 h post-treatment using the MTS
survival assay (see legend to Figure 4 for details). The results
are shown in Figures 4A–F. These data show that overexpres-
sion of MPG in MDA-MB231 cells does not alter the cyto-
toxicity of N7-ethyl-adducted lesions, N7-aminoethylguanine
or N3-aminoethyladenine adducts, O6-chloroethylguanine
adducts, N7-adducted nitrogen mustard monoadducts or
crosslinks, extracyclic guanine monoadducts or crosslinks,
or cisplatin crosslinks. MPG-dependent cytotoxicity in
MDA-MB231 cells appears to be specific to 7-meG adducts
generated by monofunctional methylating agents.
DISCUSSION
We have previously shown that MPG overexpression
sensitizes breast cancer cells to the effects of DNA alkylation,
manifested as high levels of baseless and strand-broken DNA
that ultimately lead to considerable increases in cell death (8).
The goal of this study was to understand the mechanism by
which overexpression of MPG increases sensitivity to alkylat-
ing agents in MDA-MB231 cancer cells. The data presented
here support the hypothesis that the observed cytotoxicity is
caused by rapid conversion of 7-meG adducts into toxic repair
intermediates sites by MPG. 7-meG is not a cytotoxic lesion
and overexpression of MPG, in the absence of exposure to
DNA alkylation damage, is also not cytotoxic; thus, this study
reveals a novel synthetic cytotoxicity uniquely observed in
MPG-overexpressing cells exposed to alkylation damage.
Two MPG mutants deficient in either substrate binding or
excision were used in this study to examine the requirement
for MPG glycosylase activity in generating alkylation sensit-
ivity. Overexpression of these two inactive mutants did not in
either case confer the sensitivity seen with wild-type MPG
(Figure 1), demonstrating that both MPG binding and excision
of substrate bases are necessary to confer the dramatic sens-
itivity to alkylation previously seen (8). MPG lesion binding
alone is insufficient. The obvious implication is that the pro-
ducts of MPG excisional activity are directly responsible for
increasing toxicity, providing further evidence that unrepaired
AP sites and their downstream strand-broken counterparts lead
to the increased toxicity observed in MPG-overexpressing
cells.
Previous studies have established that the E125A and
Y162A MPG mutants employed here assume a near-native
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Figure 2. Survival of Me-lex-treated MDA-MB231 cells overexpressing MPG.
MPG-overexpressing cells were treated with Me-lex at the indicated
concentrations and survival was determined as described in Materials and
Methods. Data points are the average of >10 independent experiments.
Two-way ANOVA analysis was used to evaluate statistical significance.
There were no statistically significant differences between the vector and
MPG-expressing cells.
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Figure 3. High-performance liquid chromatography (HPLC) analysis of 7-meG lesions per 106 nt in the DNA of adenovirally infected MDA-MB231 cells at various
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3D structure, despite their aberrant enzymatic function (12).
It is therefore unlikely that MPG-induced cytotoxicity results
from any other function of the enzyme, including its proposed
interaction with the nucleotide excision repair protein hHR23
(38), a function which should be conserved in E125A and
Y162A.
MPG has broad specificity for a number of damaged DNA
bases. We therefore proceeded to investigate the role of
specific alkylated bases in MPG overexpression-induced
alkylation sensitivity. The majority of base damage induced
by methylation is removed by MPG, including the principal
adducts 3-meA and 7-meG (10). Treatment of MPG-
overexpressing cells with the minor groove methylating
agent Me-lex (23), which selectively introduces >99%
3-meA adducts, was performed in order to discover the
contribution of 3-meA to MPG-induced sensitivity. Results
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showed that increased exogenous expression of MPG caused
no change in the survival response to Me-lex. These experi-
ments clearly demonstrate that 3-meA removal is not involved
in producing sensitivity to alkylation, despite the fact that
MPG is able to recognize and excise 3-meA lesions from
DNA. One explanation for this result is that the cytotoxicity
of 3-meA may be roughly equivalent to the cytotoxicity of
downstream intermediates generated during BER of 3-meA.
Such an exchange, therefore, even at an increased rate, would
not be expected to significantly alter cell survival.
The hypothesis that imbalanced BER has cytotoxic con-
sequences is based on the assumption that downstream repair
intermediates can be more cytotoxic than the DNA lesions that
trigger repair. Thus, it is relevant to note that 3-meA is intrins-
ically cytotoxic, because it inhibits DNA polymerases (39,40),
but 7-meG, a more abundant DNA lesion, is neither cytotoxic
nor mutagenic (29,30). In fact, 7-meG does not appear to have
any impact on cell viability. Thus, 7-meG is a likely candidate
for the lesion associated with MPG-dependent alkylat-
ing agent-induced cytotoxicity because incomplete repair of
7-meG, in contrast to 3-meA, could potentially be more
deleterious to the cell than no repair at all.
It is also important to note that MPG removes 3-meA
and 7-meG adducts with very different enzyme kinetics.
When present at its average endogenous level, MPG excises
7-meG much more slowly than it excises 3-meA (t1/2 = 18 h
versus 1 h, respectively). For 3-meA, the rate-limiting step
occurs late in the BER pathway, whereas for 7-meG, the rate-
limiting step is MPG excision. Furthermore, because 7-meG is
abundant and its repair is slow, excision could readily become
saturated in wild-type cells with relatively low endogenous
MPG (41), and this would not be expected to occur for 3-meA.
Increased levels of MPG may therefore selectively increase
the excision of 7-meG because of differential enzyme kinetics,
supporting the hypothesis that MPG overexpression rapidly
converts 7-meG into toxic baseless and strand-broken
intermediates and leads to increased cytotoxicity following
alkylating agent exposure.
This hypothesis was tested by quantitative HPLC-ECD
and immuno-slot-blot analyses of 7-meG adducts in MPG-
overexpressing cells (Figure 3). The results show that the
removal of 7-meG adducts is much faster and more extensive
in MPG-overexpressing cells than in wild-type cells. This
confirms that heightened MPG activity is able to increase
the normally slow rate of 7-meG excision, shifting the rate-
limiting step downstream and leading to the accumulation
of toxic repair intermediates. These results strongly implicate
7-meG removal as the mechanism by which MPG over-
expression causes sensitivity to alkylating agents.
As demonstrated in this and previous work (8), alkylating
agents that generate 7-meG DNA adducts have increased cyto-
toxicity in cells with heightened levels of MPG. We explored
the specificity of this effect using a number of agents that
append other forms of damage to guanine. No sensitivity
was seen to any of the agents tested, providing further
evidence that MPG overexpression exclusively generates
sensitivity to compounds that produce 7-meG in the DNA.
This further strengthens the hypothesis that rapid conversion
of 7-meG adducts into toxic abasic sites and strand breaks is
responsible for the increased toxicity of alkylating agents in
MPG-overexpressing cells.
CONCLUSION
The results presented here provide insight into BER and the
consequences of alkylation damage, and have important
implications for clinical chemotherapy.
The rapid removal of 7-meG lesions by increased MPG con-
verts innocuous base changes into toxic repair intermediates
that cannot be adequately handled by downstream BER
enzymes. The result is a dramatic increase in cell death. This
mechanism confirms that uncoordinated handling of even harm-
less DNA changes can be highly detrimental to the cell, and it
underscores the importance of repair pathway management.
These experiments demonstrate that cells risk extreme
toxicity to reverse changes to their genetic material and that
intervening into these repair mechanisms can alter cell sur-
vival. We believe that the results of this study have novel
implications for cancer chemotherapy. Because MPG over-
expression, which in and of itself is non-toxic, can convert
a benign DNA adduct into a highly toxic one by saturating
BER, two non-toxic therapies can be used to create cytotox-
icity. Of course, the sensitizing effects of MPG overexpression
toward 7-meG could be expected to occur in normal as well as
cancer cells. However, if independent tumor-targeting strat-
egies, each with distinct tissues of non-specificity, were used
for both MPG gene delivery and 7-meG drug delivery, even
imprecise targeting could be overcome as the two therapies
coincide to produce tumor-specific cell death. The result
would be more effective and more specific chemotherapy,
leading to decreased peripheral toxicity and improved cancer
elimination.
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